A B S T R A C T Human platelets have binding sites for plasma coagulation Factor Xa that are available only after the platelet release reaction. Platelets from 15 normal donors bound 216±52 (SD) molecules of Factor Xa per platelet. The association of Factor Xa with its platelet surface receptor results in a 300,000-fold increase in the catalytic activity of Factor Xa in forming thrombin from prothrombin. The turnover number for platelet-bound Factor Xa was 1,850+460 mol thrombin/ ml per min per mol Factor Xa in experiments with platelets from 15 normal donors. Platelets from five patients with varying degrees of Factor V deficiency were investigated to determine whether or not coagulation Factor V participates in either aspect of the Factor X.-platelet interaction. The binding of Factor Xa to platelets and the accompanying increase in rate of thrombin formation were either reduced in parallel or absent in each case with values ranging from 0 to 45% of control values. The apparent affinity of Factor Xa from Factor V-deficient patients was normal when platelet binding was detected. The supernate from thrombin-treated control platelets, which contains Factor V activity, corrected the Factor Xa binding deficiency of the platelets from three patients tested. Immunoreactive Factor V determined with an homologous antibody corresponded to the functional Factor V activity of platelets from one patient with Factor V deficiency, suggesting that the patient's platelets have a decreased amount of normal Factor V.
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The ability of platelets from the patients to bind Factor Xa and increase the rate of thrombin formation correlated with the severity of each patient's bleeding disorder better than the plasma level of Factor V. The results indicate that Factor V is required for the Factor X.-platelet interaction and that thrombin formation at the platelet surface is important in normal hemostasis. INTRODUCTION We have previously reported the appearance ofbinding sites specific for Factor Xa on the surface of human platelets after the platelet release reaction (1) . The Factor Xa-platelet binding reaction has the following characteristics (1-2): (a) there are 200 sites per platelet with an apparent association constant of 3 x 10'0M-1; (b) binding is rapidly reversible suggesting that it occurs at the platelet surface; (c) calcium is required for the reaction; (d) closely related coagulation factors, such as prothrombin, thrombin, Factor X, diisopropylphosphoryl Factor Xa, Factor IX, and Factor IXa do not displace Factor Xa from the binding sites; (e) bound Factor Xa is 300,000-fold more active than free Factor Xa in converting prothrombin to thrombin; (f) Factor Xa binding sites are not present in intact human lymphocytes or erythrocytes.
Factor V is known to cause an increase in the enzymatic conversion of prothrombin to thrombin by Factor Xa, and Factor V binds to agarose-linked Factor Xa in the presence of calcium ions (3). Factor V activity associated with isolated platelets was reported thirty years ago (4) (5) . The activity is contained within platelets until stimulation (e.g., collagen) or disruption (freeze thawing) causes its release (6, 7) . Therefore, it seemed likely that Factor V might be involved in the interaction of Factor Xa with platelets. We have demonstrated (2) that an antibody specific for Factor V (2, 8) blocks both Factor Xa binding to platelets and the accompanying increase in the rate of thrombin formation. We now report that Factor V from platelets, which is available only after the release reaction, is essential for Factor Xa binding based on experiments with platelets from five patients with varying degrees of congenital Factor V deficiency.
V human immunoglobulin (Ig)G, and for iodinating Factor Xa are described elsewhere (1, 2) . The methods for measuring thrombin generation and l25I-Factor X. binding to washed platelets are also detailed in these reports (1, 2 24 .4 mM monosodium phosphate, and 1 mg/ml glucose). Platelets from the second patient (K. S.) and the control were isolated, tested immediately for their ability to increase the rate of thrombin formation by Factor Xa, and flown to St. Louis (11-h delay) for further experiments where similar rates of thrombin formation were observed. Later we determined that blood samples collected in 5.7 mM EDTA in plastic syringes can be left at room temperature for at least 8 h with no apparent effect on the final yield or characteristics ofthe isolated platelets. Therefore whole blood samples from the final three patients (S. G., D. S., and R. G.) and the control were flown to St. Louis (4-h delay).
Plasma levels of all coagulation factors other than Factor V were normal for E. N., K. S., and R. G. S. G. and D. S. have combined Factor V and Factor VIII deficiency with plasma Factor VIII levels of 15 (9) . The purification scheme was modified by redissolving the fibrinogen in 10% of the original plasma volume after the first 2.0 M /3-alanine precipitation, treating with 5 mM diisopropylfluorophosphate for 30 min, and adding buffer containing 1 mM benzamidine hydrochloride (Sigma Chemical Co., St. Louis, Mo.), 0.1 mM phenylmethylsulfonylfluoride (Sigma Chemical Co.), and 10 mM 6-aminohexanoic acid (Eastman Chemical Products, Inc., Kingsport, Tenn.) to the original plasma volume. The final product was stored at -50'C in 0.15 M sodium chloride containing 5 mM trisodium citrate and 20 mM Tris-HCl, pH 7.5. The blank time for the Factor V assay with this fibrinogen was >5 min.
RESULTS
Factor V assay. Fig. 1 Factor V-Deficient Platelets Lack Factor Xa Binding Sitesgeneous, so this estimate may be erroneous. The bovine Factor V standard is stable (2) and was used to estimate the quantity of platelet Factor V as outlined below. We do not imply that the platelet Factor V corresponds to bovine Factor V in absolute quantity. Thrombin-induced ["4Clserotonin release from platelets. Because both Factor Xa binding and enhanced rate of thrombin formation occur only after platelets undergo the release reaction, platelets from each patient were tested for their ability to secrete [14C]serotonin in response to low levels of thrombin. Control platelets (J. M.) consistently underwent maximal release in 2 min with 0.5 U thrombin/ml with 50%o of maximal release at 0.045 U thrombin/ml. Platelets from all five patients also showed maximal release with 0.5 U thrombin/ml with 50% of maximal release at values of 0.022 (E. N.), 0.024 (K. S.), 0.025 (S. G.), 0.040 (D. S.), and 0.020 (R. G.) U thrombin/ml. These values are all within the range observed for platelets from normal donors (0.01-0.05 U thrombin/ml).
Rates of thrombin formation by Factor Xa in the presence of platelets. Fig. 2 shows the increase in thrombin concentration with time after the addition of Factor Xa to reaction mixtures containing platelets, prothrombin, Ca++, and 0.5 U thrombin/ml. The thrombin in the initial mixture was used to cause the platelet release reaction. Data for the control and for two patients are shown in Fig. 2 . The values shown for the control were determined during experiments with platelets from K. S. but are very similar to values obtained while testing platelets from E. N. The rate of thrombin formation without added platelets was 0.014 U thrombin/ml per min when 1 ,ug Factor Xa was added. Control platelets increased this rate to 3.00 U thrombin/ml per min when only 5 ng Factor X./ml was tested (2) . The pH of the buffer was adjusted for studies with platelets from the remaining patients so that the actual pH in the reaction mixtures was 7.4. The rates measured after addition of 5 ng Factor X./ml were: control, 5.6; S. G., 2.5 (44%); D. S., 2.0 (36%); and R. G., 0.05 (1%) U thrombin/ ml per min. The percentage values in parentheses relate the patient values to the control. Except for the experiment with R. G.'s platelets, these rates were determined after they became constant, which took proportionally longer in the cases where the final rate was lower. The rate for R. G.'s platelets, undetectable for 30 min, was measured at 3 h and may have been still increasing slightly.
14 normal donors (seven male and seven female) were divided into two groups that were studied on separate days. The control (J. M.) was the eighth member of each group. Isolated platelets were tested for their ability to increase thrombin formation by 5 ng/ml of Factor Xa. The mean was found to be 5.63+0.92 (SD) U thrombin/ml per min); the value for the control was 5.25 in both of these experiments.
Binding of 1251-Factor Xa to released platelets. Steady-state binding of 125I-labeled Factor X. to platelets was investigated at concentrations from 0.5 to 20 ng/ml. As previously described (2), the time required to reach maximal binding increases as the concentrations of 125I-Factor Xa decreases. Longer times were also necessary for optimal binding at a given l25I-Factor Xa concentration to platelets from patients with decreased Factor V than for binding to control platelets. The reason why the time necessary to reach apparent steady-state binding (and maximal thrombin formation) depends upon both Factors Xa and V concentrations remains obscure. Binding of 125I-Factor Xa decreases when prothrombin has mostly been converted to thrombin, so a time-course from 15 to 120 min was followed with a nonspecific binding correction, which was <10% of total binding (duplicate reaction mixture plus 100-fold excess unlabeled Factor Xa) (2), for each data point (and for each platelet preparation) at each level of 125I-Factor Xa. The final concentration dependence of 1251-Factor Xa binding reported for each platelet preparation was constructed from the points ofmaximal specific binding.
Platelets from E. N. demonstrated no specific 125I1 Factor Xa binding when concentrations from 1 ng to 1 ,ug/ml were tested in incubations for up to 3 h. Fig. 3 shows 125I-Factor Xa binding to platelets from the control and from K. S. Analysis of the data by a double reciprocal plot showed that the number of re- ceptors rather than the apparent association constant (3.1 x 1010M-1) is reduced with platelets from K. S., suggesting a deficiency of normal Factor V molecules. In this experiment, control platelets bound 1.17 ng 1251-Factor Xa/108 platelets whereas K. S. platelets bound 15% of that value (0.18 ng 1'25I-Factor X,/108 platelets). Binding data for the remaining three patients is shown in Fig. 4 . When these data were analyzed by double-reciprocal plots (not shown) it was found that binding was reduced relative to the control (1.22 ng/ 108 platelets) to 45% for S. G. (0.55 ng/108 platelets) and 34% for D. S. (0.41 ng/108 platelets). As found with platelets from K. S., binding to platelets from S. G. and D. S. showed the same apparent association constant (3.3 x 10'0M-1). It was not possible to measure binding accurately with platelets from R. G. because specific binding was a small fraction (<10%) of total binding and because we could not demonstrate saturation of the small amount of specific binding with respect to time or concentration of 125I1Xa. The maximal specific binding observed was <4% (0.05 ng/108 platelets) of the control for 125I-Factor Xa concentrations up to 20 ng/ml incubated for 120 min.
Binding data for platelets from the 14 normal donors averaged 1.65+0.04 ng 125I-Factor Xa/108 platelets at saturation; in these experiments platelets from the control bound 1.15 ng Factor Xa/ml, whereas bound to the platelet only 1-2 ng Factor Xa/ml are present (2) .
Correction of the Factor Xa binding defect of platelets from Factor V-deficient platelets by the supernate from thrombin-treated control platelets. In preliminary experiments we observed that treatment of platelets at high concentrations (2 x 109/ml) with thrombin 5 U/ml followed by immediate sedimentation of the platelets through oil in a microfuge at 12,000 g for 2 min yielded a supernatant fraction containing factor V activity (0.5 U/108 platelets, where normal human plasma has 1 U/ml). Osterud et al. have shown that platelet Factor V is activated (probably Factor Va) and thus the platelet Factor V activity reflects less mass of Factor V than does the assay of Factor V in plasma. Indeed the assay of dilutions of platelet Factor V (?Va) in our assay gave a slope similar to the bovine Factor Va studied.
Platelets from S. G., D. S., R. G., and the control were incubated at 108/ml in reaction mixtures containing prothrombin, 5 ng 'uI-Factor X./ml and the fraction that contains platelet Factor V obtained from normal platelets as described above (1.0 U Factor V) from 2 x 108 control platelets. Nonspecific binding was determined by addition of 1 ,ug unlabeled Factor Xa/ml. Specific binding, measured in duplicate after 15 Freshly isolated platelets from E. N. were incubated at 108/ml with bovine 125I-Factor Va (0.2 ,ug/ml, 135 cpm/ng Factor V), 5 mM CaCl2, 75 ,ug prothrombin/ml, and where indicated 10 ng Factor Xa/ml and 10 ,mg unlabeled Factor Va/ml. Reaction mixtures were incubated 15 min at 25°C and the platelets were collected by sedimentation through oil as described previously (2) . Bovine Factor Va was labeled with the procedure described previously for labeling Factor Xa (2). 828 J. P. Miletich, D. W. Majerus, and P. W. Majerus sedimented and cannot be resuspended to carry out a two-stage binding assay. Inhibition of platelet accelerated rate of thrombin formation by an anti-Factor V human IgG. We have previously reported (2) that a highly purified, homogeneous IgG paraprotein isolated from the plasma (provided by Dr. Helen Glueck, University of Cincinnati) of a patient with an acquired inhibitor to Factor V (8), causes reduced Factor Xa binding and thrombin formation when incubated with thrombin-treated platelets. The antibody is specific for Factor V and cross-reacts with purified bovine Factor V. The inhibition of both binding and thrombin formation is overcome with time after addition of Factor Xa, presumably because the affinity of Factor Xa is greater than that of the antibody. IgG from normal human plasma has no effect on the Factor Xa-platelet interaction even at 1,000-fold higher concentrations.
We measured the effect of the anti-Factor V IgG by incubating it at varying concentrations (0.05-2.0 ,Ag/ml) for 20 min with thrombin-treated platelets. After the addition of prothrombin (70 ,g/ml) and Factor Xa (5 ng/ml) we measured thrombin formation with time.
The rate of thrombin formation was determined at the earliest time a particular platelet preparation reached the maximal rate in the absence of added inhibitor. The results for control and K. S. platelets are shown in Fig. 5 . It appears that the patient's platelets do not have a significant amount of nonfunctional cross-reactive Factor V because only about one-sixth the concentration of anti-Factor V antibody was necessary to achieve the same initial degree of inhibition relative to control platelets. Feinstein et al. were also unable to detect cross-reacting material in plasma from the same patient (K. H. in their study) with a different homologous anti-Factor V antibody (10) .
Plasma Factor V. Plasma from each patient and the control was assayed for Factor V. The control plasma (J. M.) had 85% of the activity of pooled normal plasma and was the same for each experiment. Plasmas from E. N., K. S., and R. G. had no Factor V activity when diluted 1,000-fold and prolonged the blank time of the assay when used at higher concentrations. Plasma samples from S. G. and D. S. had 1.6 and 2.4% of the control level when assayed at fivefold dilution. However, the apparent activity in their plasmas increased slightly with further dilution; 1.9 and 2.7% at 12.5-fold, 2.2 and 3.0% at 25-fold, 2.5 and 3.4% at 50-fold, and 3.1 and 3.8% at 125-fold. No activity was detectable at higher dilutions. The values at the highest dilution were taken as the patients' plasma Factor V levels as shown in Table II .
In mixing experiments all of the plasmas reduced the activity of the control plasma by 10-20% . The nature of these slight inhibitions was not determined, but their presence prevented a straightforward use of the Factor Xa/ml, thrombin formation was determined at various times. The rates presented were determined at the time when thrombin formation was maximal in reactions without the Factor V inhibitor. The extrapolated lines approximate the amount ofantibody required to inactivate the Factor V in each sample.
anti-Factor V antibody to check for low levels of plasma cross-reacting material. Clinical severity of Factor V deficiency. Each patient was interviewed for a history of bleeding problems. Only E. N. and R. G. regarded themselves as "bleeders" and felt that their life styles had been severely restricted by their problem. Both first had trouble at an early age (6-7 yr) and both have required transfusions (1-2 episodes per year) throughout most of their adolescent and adult lives. Both have had frequent bruises, after minor trauma, that healed slowly. In contrast, the remaining three patients, K. S., S. G., and D. S., have had mild problems and do not consider themselves handicapped. Each was diagnosed as having a bleeding problem at age 24 or older. Other than for prophylaxis they have not required transfusions. Episodes of broken bones, a concussion, tooth extractions, childbirth, and surgery with minimal or no Factor V-Deficient Platelets Lack Factor Xa Binding Sites (3) . Because Factor Va is at least 60-fold more active than Factor V (14), the mass of Factpr Va in platelets is probably very small compared to Factor V in plasma as suggested previously by immunoassay of platelet and plasma Factor V (7).
All five of the patients in this study have very low plasma Factor V levels relative to the control, but their platelets bind 0-45% of the normal amount of Factor Xa. Lewis and Ferugson (15) also reported a Factor V-deficient patient whose plasma level was zero whereas the platelet level was 5-10% of normal. This might indicate that the activities are distinct molecules or that there is a preferential distribution of Factor V favoring platelets at low total levels. On the other hand, it might simply reflect an underestimate of the patients' plasma activity, as a result of the presence of acquired inhibitors or an abnormal molecule with rapid clearance, for example. Alternatively, we may underestimate the total amount of Factor V (Va) in normal platelets. Because only 200 molecules of Factor Xa bind per platelet, only a similar small number of Factor V molecules can participate functionally in assays of Factor Xa binding or thrombin formation. Thus, if normal platelets contain a 10-fold excess of Factor V, then platelets with only 1% of this amount might appear to have 10% by our assays. We did not measure the activity of Factor-V released from the Factor V-deficient patients by our coagulation assay except in the case of E. N. who had no detectable activity. However, our results demonstrate that the Factor Xa binding capacity of platelets is a more reliable indicator of the clinical status of patients with Factor V deficiency than the level ofplasma Factor V, even when a very sensitive and specific assay is employed for the latter.
The enzymatic activity of Factor Xa is increased 300,000-fold when it is bound at the platelet surface. Thus, it is likely that significant thrombin formation occurs at the platelet surface during normal hemostasis and that platelet surface Factor V activity of platelets is involved. Borchgrevink and Owren (16) have reported that platelet transfusion corrected the bleeding time of a Factor V-deficient patient for a time approaching the life span of platelets (t412 5-6 days) without elevating the plasma level of Factor V, whereas plasma transfusion was effective for a much shorter time (tl2 12-15 h). All five patients presented here have very low plasma Factor V. Yet those whose platelets can bind a significant fraction of the normal amount of Factor Xa have mild bleeding disorders, whereas those whose platelets cannot bind Factor Xa have serious problems. These results not only demonstrate that Factor V is ah essential participant in the platelet-Factor Xa interaction, but also underscore the probability that platelet surface thrombin formation is an important event in maintaining normal hemostasis.
